Shorla Pharma Sees Opportunity In Re-Innovated Oncology Drugs
Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.
You may also be interested in...
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.